Pacific Edge Retail Offer Closes Over Subscribed

Company Announcement
18 October 2021

PACIFIC EDGE RETAIL OFFER CLOSES OVER SUBSCRIBED

Cancer diagnostics business, Pacific Edge, (NZX: PEB) advises that its Retail Offer (“Offer”) has closed
oversubscribed.

The Offer received very strong support from existing eligible shareholders with applications totalling NZ$80.0m,
NZ$60.0m (300%) above the NZ$20m offered. The company has accepted NZ$3.5m in oversubscriptions to take
the total raised in the Retail Offer to NZ$23.5m. The acceptance of the oversubscription allows all applicants to
receive the minimum of their application or their pro-rata allocation
1
up to the NZ$50,000 maximum under the
Offer.

The Offer is part of Pacific Edge’s capital raising announced on 23 September 2021, which included a NZ$80m
placement with new and existing shareholders that was upsized from NZ$60m due to the high demand.

Chair of Pacific Edge, Chris Gallaher, said: “We would like to thank all of the Pacific Edge shareholders who
participated in the capital raise for their strong support. Combined, the Offer and Placement total NZ$103.5m of
new capital, which will enable Pacific Edge to leverage commercial milestones and accelerate its growth strategy in
the US and other targeted markets of scale. Our company continues to make strong progress as we position our
Cxbladder suite of tests as the diagnostic product of choice for urologists and patients. The positive momentum
seen in FY21 and into the first quarter of FY22 has continued with ongoing growth in both test numbers and cash
receipts, despite the impact of Covid-restrictions on the healthcare market.”

The new shares under the Offer will be issued at a price of NZ$1.35, which represents the lower of the price paid
by investors in the Placement (NZ$1.35) and the volume weighted average price of Pacific Edge's shares on the NZX
over the 5-day trading period up to and including the closing date of the retail offer on 13 October 2021.

Settlement and allotment of the new shares is expected to occur on 20 October 2021, with trading of the shares
on the NZX and ASX to commence on the same day. Refunds of the surplus application amounts are expected to
be made to applicants by 27 October 2021.

ENDS

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

Refer to www.cxbladder.com for more information.

1
Pro rata allocation rounded down to the nearest share